Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report)’s share price was down 5.8% during mid-day trading on Wednesday after Morgan Stanley lowered their price target on the stock from $49.00 to $43.00. Morgan Stanley currently has an overweight rating on the stock. Legend Biotech traded as low as $19.52 and last traded at $19.23. Approximately 317,877 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 2,400,846 shares. The stock had previously closed at $20.41.
LEGN has been the subject of a number of other reports. Oppenheimer cut their target price on Legend Biotech from $40.00 to $25.00 and set a “market perform” rating for the company in a research report on Wednesday. HC Wainwright reiterated a “buy” rating on shares of Legend Biotech in a research report on Friday, October 30th. Benchmark reissued a “buy” rating on shares of Legend Biotech in a research note on Tuesday, July 28th. Raymond James Financial reaffirmed an “outperform” rating and set a $58.00 target price on shares of Legend Biotech in a research note on Monday, July 27th. Finally, Weiss Ratings raised shares of Legend Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Nine investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $50.85.
View Our Latest Analysis on LEGN
Insiders Place Their Bets
More Legend Biotech News
Here’s some of the latest news about LEGN:
- Positive Sentiment: Recent coverage highlights growth in CARVYKTI sales, a potential support for Legend Biotech’s commercial outlook. Is Legend Biotech (LEGN) Reasonable After CARVYKTI Sales Growth?
- Neutral Sentiment: Third-quarter results were mixed: revenue increased 32% year over year to $359.5 million, slightly below estimates, while EPS of $0.14 beat the $0.01 consensus. The earnings-call transcript provides further context on the quarter. Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript
- Negative Sentiment: Four firms lowered their price targets, signaling more cautious expectations: Morgan Stanley cut its target to $43 but kept Overweight; Oppenheimer lowered to $25 and retained Market Perform; RBC cut to $50 while maintaining Outperform; and Barclays reduced its target to $61 but stayed Overweight. Analysts Offer Insights on Healthcare Companies: Align Tech and Legend Biotech
Institutional Trading of Legend Biotech
A number of hedge funds have recently bought and sold shares of LEGN. Ieq Capital LLC acquired a new stake in shares of Legend Biotech during the third quarter valued at approximately $937,000. Public Sector Pension Investment Board boosted its stake in Legend Biotech by 3.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 26,789 shares of the company’s stock worth $533,000 after purchasing an additional 1,000 shares during the period. Russell Investments Group Ltd. boosted its stake in Legend Biotech by 484.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 68,698 shares of the company’s stock worth $1,294,000 after purchasing an additional 56,936 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in Legend Biotech by 2.1% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 177,268 shares of the company’s stock worth $3,526,000 after purchasing an additional 3,707 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Legend Biotech during the 3rd quarter worth approximately $136,000. 70.89% of the stock is owned by hedge funds and other institutional investors.
Legend Biotech Stock Performance
The firm’s 50-day simple moving average is $19.66 and its two-hundred day simple moving average is $22.12.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $359.50 million during the quarter, compared to analyst estimates of $361.46 million. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The company’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.05) earnings per share. As a group, equities analysts anticipate that Legend Biotech Corporation Sponsored ADR will post -0.08 earnings per share for the current year.
Legend Biotech Company Profile
Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.
Featured Stories
- Five stocks we like better than Legend Biotech
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
